Arbutus Biopharma (ABUS) Operating Margin (2013 - 2026)
Arbutus Biopharma (ABUS) posted Operating Margin of 94.3% for Q1 2026, up 118.73% sequentially from 503.33% in Q4 2025, and up 155116.0% YoY from N/an in Q1 2025.
Arbutus Biopharma (ABUS) Operating Margin (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported Operating Margin for 14 years, with the latest figure at 94.3% in Q1 2026.
- Quarterly Operating Margin rose 155116.0% year-over-year to 94.3% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 81.72% (up 137260.0% YoY) and the FY2025 annual result came in at 270.96%, up 96577.0% from the prior year.
- Operating Margin grew to 94.3% in Q1 2026 per ABUS's latest filing, from 503.33% in the prior quarter.
- Over five years, Operating Margin peaked at 94.3% in Q1 2026 and troughed at 1636.86% in Q3 2025.
- A 5-year average of 671.9% and a median of 462.82% in 2023 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2024 and 2026: Operating Margin slumped 113838 bps in 2024, then jumped 155116 bps in 2026.
- Over 5 years, Operating Margin stood at 361.28% in 2022, then slumped by 168 bps to 967.23% in 2023, then climbed by 8 bps to 885.2% in 2024, then surged by 43 bps to 503.33% in 2025, then soared by 119 bps to 94.3% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 94.3%, 503.33%, and 1636.86% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | -588.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -588.17% |
| Mar 31, 2026 | 94.30% |
| Dec 31, 2025 | -503.33% |
| Sep 30, 2025 | -1,636.86% |
| Jun 30, 2025 | 13.86% |
| Mar 31, 2025 | -1,456.86% |
| Dec 31, 2024 | -885.20% |
| Sep 30, 2024 | -1,601.19% |
| Jun 30, 2024 | -1,250.46% |
| Mar 31, 2024 | -1,263.90% |
| Dec 31, 2023 | -967.23% |
| Sep 30, 2023 | -462.82% |
| Jun 30, 2023 | -395.29% |
| Mar 31, 2023 | -260.40% |
| Dec 31, 2022 | -361.28% |
| Sep 30, 2022 | -299.24% |
| Jun 30, 2022 | -99.07% |
| Mar 31, 2022 | -87.23% |
| Dec 31, 2021 | -648.66% |
| Sep 30, 2021 | -551.14% |